The human epidermal growth factor receptor-2 (HER2) overexpresses with a significant proportion in breast, ovarian and gastric cancers and may serve as a tumor-targeting marker for the treatment of patients with HER2-positive cells (14, 15). Here, ERBB2 is linked to neoplasm.